Your browser doesn't support javascript.
loading
Therapeutic Efficacy of a Bivalent Inhibitor of Prostate-Specific Membrane Antigen Labeled with 67Cu.
McInnes, Lachlan E; Cullinane, Carleen; Roselt, Peter D; Jackson, Susan; Blyth, Benjamin J; van Dam, Ellen M; Zia, Nicholas A; Harris, Matthew J; Hicks, Rodney J; Donnelly, Paul S.
Afiliación
  • McInnes LE; School of Chemistry, Bio21 Molecular Science and Biotechnology Institute, University of Melbourne, Parkville, Victoria, Australia.
  • Cullinane C; Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria, Australia.
  • Roselt PD; Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; and.
  • Jackson S; Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria, Australia.
  • Blyth BJ; Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria, Australia.
  • van Dam EM; Clarity Pharmaceuticals Ltd., Eveleigh, New South Wales, Australia.
  • Zia NA; School of Chemistry, Bio21 Molecular Science and Biotechnology Institute, University of Melbourne, Parkville, Victoria, Australia.
  • Harris MJ; Clarity Pharmaceuticals Ltd., Eveleigh, New South Wales, Australia.
  • Hicks RJ; Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria, Australia.
  • Donnelly PS; Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; and.
J Nucl Med ; 62(6): 829-832, 2021 06 01.
Article en En | MEDLINE | ID: mdl-33067341
ABSTRACT
Radionuclide therapy targeting prostate-specific membrane antigen (PSMA) is promising for prostate cancer. We previously reported a ligand, 64Cu-CuSarbisPSMA, featuring 2 lysine-ureido-glutamate groups. Here, we report the therapeutic potential of 67Cu-CuSarbisPSMA.

Methods:

Growth of PSMA-positive xenografts was evaluated after treatment with 67Cu-CuSarbisPSMA or 177Lu-LuPSMA imaging and therapy (I&T).

Results:

At 13 d after injection, tumor growth was similarly inhibited by the 2 tracers in a dose-dependent manner. Survival was comparable after single (30 MBq) or fractionated (2 × 15 MBq, 2 wk apart) administrations.

Conclusion:

67Cu-CuSarbisPSMA is efficacious in a PSMA-expressing model of prostate cancer.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Radioisótopos de Cobre / Glutamato Carboxipeptidasa II / Antígenos de Superficie Límite: Animals Idioma: En Revista: J Nucl Med Año: 2021 Tipo del documento: Article País de afiliación: Australia
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Radioisótopos de Cobre / Glutamato Carboxipeptidasa II / Antígenos de Superficie Límite: Animals Idioma: En Revista: J Nucl Med Año: 2021 Tipo del documento: Article País de afiliación: Australia